TrakCel enters into new agreement with Cell and Gene Therapy Catapult
TrakCel has announced it will incorporate its supply chain management platform into Cell and Gene Therapy Catapult’s large scale manufacturing center.
The partnership will enable CGT Catapult collaborators to use established software to track cell therapies across the whole supply chain.
In addition to the manufacturing center, the TrakCel technology will link with Thermo Fisher Scientific’s new Fisher Bioservices CryoHubSM. It will also further establish the Stevenage Bioscience Catalyst as an emerging cell and gene therapy cluster.
The partnership will provide the world’s first supported GMP manufacturing base for cell and gene therapies enabling visibility across the entire manufacturing and supply process.
Keith Thompson, Chief Executive Officer of the Cell and Gene Therapy Catapult says.
“We are pleased to provide our partners at the manufacturing centre with complementary tracking technology, such as the TrakCel Cellular Orchestration Platform, as we work to not only offer GMP manufacturing support in Stevenage but also ease our collaborator’s access to a fully developed, high quality global supply chain.”
Ravi Nalliah, CEO of TrakCel says.
“The cell therapy sector is now starting to move from considerations around clinical development to commercialisation, and multi-layered supply chains involving many more patients, individuals and organisations. Patients will rely on the sector to ensure supply chains involve the adequate transportation of valuable cellular material in the right conditions. As the most-advanced software developer for global cell and gene therapy supply chain tracking and orchestration, TrakCel is contributing its tracking capabilities to a range of international collaborations and firms. This partnership between CGT Catapult, TrakCel and Fisher BioServices will deliver the most technologically advanced and secure large-scale GMP manufacturing base for cell and gene therapies in the world.”
Read the full story here.